The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The plant indole alkaloid ibogaine has shown promising anti-addictive properties in animal studies. Ibogaine is also anti-addictive in humans as the drug alleviates drug craving and impedes relapse of drug use. Although not licensed as therapeutic drug and despite safety concerns, ibogaine is currently used as an anti-addiction medication in alternative medicine in dozens of clinics worldwide. In recent years, alarming reports of life-threatening complications and sudden death cases, temporally associated with the administration of ibogaine, have been accumulating. These adverse reactions were hypothesised to be associated with ibogaine’s propensity to induce cardiac arrhythmias. The aim of this review is to recapitulate the current knowledge about ibogaine’s effects on the heart and the cardiovascular system, and to assess the cardiac risks associated with the use of this drug in anti- addiction therapy. The actions of 18-methoxycoronaridine (18-MC), a less toxic ibogaine congener with anti-addictive properties, are also considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drew, B. J., Ackerman, M. J., Funk, M., Gibler, W. B., Kligfield, P., Menon, V., Philippides, G. J., Roden, D. M., & Zareba, W. (2010) · Circulation · doi:10.1161/circulationaha.109.192704 · Cited by 821
GLICK, S. D., MAISONNEUVE, I. M., & SZUMLINSKI, K. K. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05211.x · Cited by 92 · cited 10×
“18-MC’s affinity for muscarinic receptors is at least two-fold less than that of ibogaine [4,49].”
BackgroundResultInfluential(2001) · The Alkaloids: Chemistry and Biology · doi:10.1016/s0099-9598(01)56006-x · Cited by 64
Cited by
A non-hallucinogenic psychedelic analogue with therapeutic potential
Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., et al. (2021) · Nature · doi:10.1038/s41586-020-3008-z · Cited by 473
Role of plant alkaloids on human health: A review of biological activities
Debnath, B., Singh, W. S., Das, M., Goswami, S., Singh, M. K., Maiti, D., & Manna, K. (2018) · Materials Today Chemistry · doi:10.1016/j.mtchem.2018.05.001 · Cited by 384
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“The neuropharmacology of ibogaine is complex and remains incompletely understood (Koenig & Hilber, 2015; Mash et al., 1998, 2001).”
BackgroundStudies with psychedelic drugs in human volunteers
Sellers, E. M., Romach, M. K., & Leiderman, D. B. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.029 · Cited by 42
Deciphering Ibogaine’s Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses
Hwu, C., Havel, V., Westergaard, X., Mendieta, A. M., Serrano, I. C., Hwu, J., Walther, D., Lankri, D., Selinger, T. L., He, K., et al. (2025) · doi:10.1101/2025.03.04.641351 · Cited by 7
“12 Nevertheless, many individuals desperate for relief from their suffering have sought ibogaine treatment in clinics abroad, a growing trend that has provided pilot clinical observations.”
Metadata
- Authors
- Koenig, X., & Hilber, K.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2015-01-29
- Volume
- 20
- Issue
- 2
- Pages
- 2208-2228
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2020659752
- Cited by
- 125
- References
- 3
- FWCI
- 9.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation. https://app.cochat.ai/papers/10.3390/molecules20022208
- The paper
- Koenig, X., & Hilber, K. (2015). The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation. Molecules. https://doi.org/10.3390/molecules20022208
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.